ArticleAmerican journal of epidemiology2017
Serum Levels of 1,5-Anhydroglucitol and Risk of Incident End-Stage Renal Disease.
Article in American journal of epidemiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.Diabetes, obesity & metabolism · 2019Trial
- 1,5-Anhydroglucitol: From Short-Term Glycemic Monitoring to Risk Stratification of Diabetes Complications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study.Diabetes, obesity & metabolism · 2026Article
- Assembled human microbiome and metabolome in chronic kidney disease: Dysbiosis a double-edged sword interlinking Circ-YAP1, Circ-APOE & Circ-SLC8A1.Toxicology reports · 2025Article
- The clinical potential of 1,5-anhydroglucitol as biomarker in diabetes mellitus.Frontiers in endocrinology · 2024Review
- The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications.Frontiers in endocrinology · 2024Review
- The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice.Nature communications · 2022Article
- Serum Metabolites and Kidney Outcomes: The Atherosclerosis Risk in Communities Study.Kidney medicine · 2022Article
- 1,5-Anhydroglucitol Predicts Mortality in Patients with HBV-Related Acute-on-chronic Liver Failure.Journal of clinical and translational hepatology · 2022Article
- Assessment of glycemia in chronic kidney disease.BMC medicine · 2022Review
- Circulating short and medium chain fatty acids are associated with normoalbuminuria in type 1 diabetes of long duration.Scientific reports · 2021Article
- Plasma Endothelin-1 and Risk of Death and Hospitalization in Patients Undergoing Maintenance Hemodialysis.Clinical journal of the American Society of Nephrology : CJASN · 2020Article
- Analysis of risk factors of metabolic syndrome using a structural equation model: a cohort study.Endocrine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Glycemic excursions, independent of average glucose, have been implicated in the development of diabetic complications. It is unknown whether low levels of 1,5-anhydroglucitol (1,5-AG) are associated with advanced stages of kidney disease independent of kidney function and glycemia. In the Atherosclerosis Risk in Communities Study (n = 13,277 from 4 US communities), we used structural equation modeling to estimate the association between serum 1,5-AG levels and end-stage renal disease (ESRD) from baseline (1990-1992) through 2013 with adjustment for demographics, risk factors, a latent variable for glycemia (diabetes status, fasting glucose, glycated hemoglobin (HbA1c), fructosamine, glycated albumin), and a latent variable for kidney function (creatinine, cystatin C, β2-microglobulin). After adjusting for demographics, risk factors, and the latent variable for kidney function, the linear spline terms representing 1,5-AG levels <6.0 μg/mL (incidence rate ratio (IRR) = 0.79, 95% confidence interval (CI): 0.70, 0.88) and 6.0-9.9 μg/mL (IRR = 0.80, 95% CI: 0.70, 0.92) were significantly associated with ESRD. After additionally adjusting for the latent variable for glycemia, low 1,5-AG levels (<6.0 μg/mL) were no longer significantly associated with ESRD (IRR = 0.92, 95% CI: 0.81, 1.05). In conclusion, low 1,5-AG levels are associated with higher risk of incident ESRD independent of baseline kidney function but not independent of glycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.